Dr. Beata Halassy, a 49-year-old virologist, self-treated her recurrent breast cancer with OVT, a method that leverages ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...

ADCs, including the widely used cancer drug Enhertu (trastuzumab deruxtecan), represent a new wave of targeted therapies.

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Medically reviewed by Lindsay Cook, PharmD If you have HER2-positive breast cancer, your options for treatment will depend on ...

A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally advanced or ...

Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...

Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs ...

“We observed that the majority of our trastuzumab resistant cell lines remain sensitive to lapatinib, providing further evidence that these two agents have independent mechanisms of resistance.

The primary objective of the present study was to assess the anti-tumor activity of a combination of trastuzumab with carboplatin and paclitaxel in patients with recurrent or refractory ovarian ...